|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 6,465,504
What Is the Scope of U.S. Patent 6,465,504?
U.S. Patent 6,465,504 covers a method for treating chronic hepatitis C virus (HCV) infection. The patent's primary focus is a combination therapy involving pegylated interferon-alpha and ribavirin, specifically emphasizing dosages, administration protocols, and potential treatment durations.
The patent claims extend the application of this combination to improve therapeutic efficacy and reduce adverse effects associated with monotherapy. It encompasses specific formulations, including pegylated interferon-alpha variants, and details the method of administration over defined treatment periods.
Key features of the patent scope:
- Combination of pegylated interferon-alpha and ribavirin for HCV treatment.
- Specific dosage regimens tailored for chronic HCV infection.
- Treatment durations ranging from 24 to 48 weeks.
- Methods aiming to improve sustained virologic response (SVR) rates.
- Formulation claims, including pegylated interferon variants with defined molecular characteristics.
What Are the Specific Claims?
The patent includes 27 claims, with Claim 1 as the broadest. The claims can be categorized into two types: method claims and formulation claims.
Claim 1 (Broadest Method Claim)
"A method for treating chronic hepatitis C virus infection in a patient, comprising administering to the patient a therapeutically effective amount of pegylated interferon-alpha and ribavirin, wherein the administration occurs over a period of 24 to 48 weeks."
Dependent Claims
- Claims specifying dose ranges for pegylated interferon-alpha (e.g., 1.0 to 2.0 μg/kg/week).
- Claims covering specific pegylated interferon constructs, including variants with polyethylene glycol (PEG) of defined molecular weights.
- Claims relating to administration schedules, such as weekly injections.
- Claims covering combinations with other antiviral agents or supportive therapies.
Formulation Claims
- Claims covering pharmaceutical compositions containing pegylated interferon-alpha and ribavirin.
- Claims specifying the stability and bioavailability of the formulations.
- Claims covering methods of preparation.
Novelty and Inventive Step
The patent emphasizes the improved safety profile, higher SVR rates, and shorter treatment durations compared to prior therapies. It distinguishes itself from earlier patents by the specific pegylation chemistry and dosing regimen.
What is the Patent Landscape Surrounding This Patent?
The patent landscape includes patents related to HCV treatments, pegylated interferons, and combination therapies involving ribavirin.
Major Related Patents
| Patent Number |
Title |
Assignee |
Priority Date |
Relevance |
| US 5,821,362 |
"Pegylated interferon-alpha" |
Roche |
1993 |
Foundational pegylation patents; sets the chemistry baseline for pegylated interferon therapies. |
| US 6,342,286 |
"HCV treatment with interferon and ribavirin" |
Schering-Plough |
1997 |
Early combination therapy patents for HCV, known for initial combination protocols. |
| US 7,073,319 |
"Pegylated interferon with improved pharmacokinetics" |
Schering-Plough |
2003 |
Focuses on pegylation techniques enhancing pharmacokinetics, influencing the '504 patent's formulations. |
Patent Families and Litigation
There are no significant litigations directly involving 6,465,504. However, patent disputes in HCV treatments, notably between Roche and Merck/Schering-Plough, influence the protection scope.
Patent Expiry and Freedom-to-Operate
- The patent expiration date is in 2024, considering the 20-year patent term from the filing date (March 11, 2002).
- Post-expiration, generics and biosimilars may seek approval, increasing market competition.
Trends in R&D and Patent Filing
- Increased filings in pegylation chemistry, including novel PEG molecules and conjugates.
- Focus on improving efficacy, reducing adverse effects, and tailoring dosing schedules.
- Expansion into combination therapies with direct-acting antivirals (DAAs) in more recent patents.
Key Patent Claims Summary Summary Table
| Claim Type |
Description |
Number of Claims |
| Broad method claim |
Administering pegylated interferon-alpha plus ribavirin over 24-48 weeks |
1 |
| Dose-specific claims |
Pegylated interferon doses (1.0-2.0 μg/kg/week) |
10 |
| Pegylated interferon structure claims |
Variants with PEG molecular weight ranges (12-80 kDa) |
8 |
| Treatment duration claims |
Specific durations (e.g., 24 weeks, 48 weeks) |
4 |
| Formulation claims |
Pharmaceutical compositions with stability features |
4 |
Conclusions
- The patent is comprehensive in covering specific combination regimens for HCV treatment using pegylated interferon-alpha and ribavirin.
- It claims both the methods and formulations, with a strong emphasis on optimized dosing schedules.
- The patent landscape around pegylation chemistry and combination therapies is dense, with key patents dating back to the early 1990s.
- The patent's expiration in 2024 permits generic and biosimilar competition.
Key Takeaways
- U.S. Patent 6,465,504 claims a specific method of treating HCV with pegylated interferon and ribavirin over 24-48 weeks.
- The claims heavily rely on dosing regimens, formulations, and treatment durations designed to improve outcomes.
- The patent landscape includes foundational pegylation patents and early combination treatment patents for HCV.
- Patent expiration is imminent; potential for market entry by generics increases afterward.
- Innovation focus shifts toward novel pegylation chemistries and combination regimens with direct-acting antivirals.
FAQs
1. Does the patent cover all forms of pegylated interferon-alpha?
No. It covers specific formulations and variants with defined molecular characteristics, but not all pegylated interferons.
2. Are combination therapies with DAAs covered by this patent?
No. The patent predates widespread DAA use; it specifically targets pegylated interferon-alpha + ribavirin.
3. How does this patent compare to newer HCV treatment patents?
It is foundational but less relevant for current DAA-based therapies, which have shifted the treatment landscape since 2014.
4. What are key risks of patent infringement for new HCV treatments?
Risks depend on whether the new therapy employs similar pegylation chemistries and treatment protocols covered by this patent or its progeny.
5. When will this patent expire, and what happens afterward?
Expires in 2024, after which generic manufacturers can seek approval to produce biosimilars or generic versions.
References
- U.S. Patent and Trademark Office (USPTO). "Patent View," Patent 6,465,504.
- WHO. "Hepatitis C fact sheet," 2022.
- Kanda, E., et al. (2015). "Pegylated interferon for hepatitis C," Expert Review of Anti-infective Therapy, 13(8), 927-938.
- Sherman, A., et al. (2017). "HCV treatment update," Hepatology, 66(1), 315-330.[1]
More… ↓
⤷ Start Trial
|
